Business
New SK Life Science, Inc. Survey Reveals Communication Gaps Between Patients and Providers That Can Impact Epilepsy Care Outcomes
As National Epilepsy Awareness Month begins on Saturday, new survey findings from SK Life Science, Inc., a global leader in treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., reveal striking communication gaps between patients and providers that can stand in the way of proper care and important treatment decisions. Notably, nearly three-quarters of people living with epilepsy report they don't share all seizures with their doctors, undersco
About this update from Sk Biopharmaceuticals Co., Ltd.
[{"type":"text","content":"Nearly 3 in 4 patients don't report all of their seizures to their doctor, highlighting risks in treatment decisions and life-saving conversations","length":150,"tagName":"p","attribs":{}},{"type":"text","content":"PARAMUS, N.J., Oct. 28, 2025 /PRNewswire/ -- As National Epilepsy Awareness Month begins on Saturday, new survey findings from SK Life Science, Inc., a global leader in treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., reveal striking communication gaps between patients and providers that can stand in the way of proper care and important treatment decisions. Notably, nearly three-quarters of people living with epilepsy report they don't share all seizures with their doctors, underscoring the importance of trust, open dialogue, and more effective treatment conversations.","length":642,"tagName":"p"},{"type":"image","alt":"SK Life Science, Inc. (PRNewsfoto/SK Life Science, Inc.)","displaySize":"","headline":null,"caption":"SK Life Science, Inc. (PRNewsfoto/SK Life Science, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":143,"url":"https://media.zenfs.com/en/prnewswire.com/fcbc1cdab3d124f1865a5bb3593285c4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jp3A3lTr1DnUN.dDiAimig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI1MjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/fcbc1cdab3d124f1865a5bb3593285c4","width":400,"height":143}},"href":"https://mma.prnewswire.com/media/2565748/SK_Life_Science_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The survey, Hope, Hesitancy, and Hard Truths: A Patient and Provider Perspective on Epilepsy Treatment, conducted by Wakefield Research among 500 patients living with epilepsy and 450 healthcare providers in the U.S. (neurologists, epileptologists, and advanced practice providers), also uncovered differences in how each group defines seizure control and approaches treatment decisions. For example, while nearly two-thirds (63%) of doctors believe it's realistic to reduce seizures by 75-100%, more than three-quarters (78%) of patients don't believe they'll ever be seizure-free. Among the survey's most significant findings:","length":644,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Treatment switching dis...